Piplartine
CAS 20069-09-4
Piplartine (CAS 20069-09-4) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 12125.266258503401 nM | 145 | - |
| - | Potency | 13869.666000000001 nM | 48 | - |
| - | EC50 | 11905.833333333334 nM | 12 | - |
| - | AC50 | 17136.5 nM | 6 | - |
| - | GI50 | 9260 nM | 5 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Piplartine used for in pharmaceutical contexts?
Piplartine (CAS 20069-09-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Piplartine?
No adverse-event association or SIDER side-effect rows are rendered for Piplartine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Piplartine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Piperlongumine with EU status "permitted".
What clinical phase is Piplartine in?
No phase 1-4 clinical development badge is rendered for Piplartine because the matched compound identifier rows do not contain a max-phase value.